BCR and chronic myelogenous leukemia, BCR-ABL1 positive: In our cohort, there are six CML patients in the TFR protocol, with imatinib discontinuation ranging from 294 to 602 days (440.33 ± 98.91 days), all of whom are in DRM or with undetected BCR::ABL1 expression for all clinical samples quantified by RT-qPCR (Figure 4).